We are pleased to announce that the paper, “Utilization of the Disease Severity Index (DSI) from the HepQuant DuO Test Enhances Clinical Decision Making in Compensated Advanced Chronic Liver Disease,” has been selected as a Journal of Clinical Medicine Editor’s Choice Article for the third quarter of 2026.
Published on January 8, 2026, the study demonstrates how the Disease Severity Index generated by the HepQuant DuO Test can provide clinically meaningful information to support decision-making in patients with compensated advanced chronic liver disease.
The journal’s editors recognized the paper for its timely and relevant subject matter and its strong citation potential. This distinction highlights the importance of improving liver disease assessment and advancing more informed, individualized patient care.
We are honored to receive this recognition and thank the study’s authors, collaborators, and research partners for their contributions to this work.